MedTrace Logo

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

NCT05472857 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-06

No results posted yet for this study

Summary

This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression

Conditions

Interventions

BIOLOGICAL

Claudin 18.2 CAR-T

treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion

Sponsors & Collaborators

  • Changhai Hospital

    collaborator OTHER

  • Suzhou Immunofoco Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Luo Tianhang, MD · Changhai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05472857 on ClinicalTrials.gov